NCT05143424

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

Phase 1 Drug-drug Interaction of Cannabidiol and Morphine in Recreational Opioid Users

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.

Detailed description

This is an inpatient, single-blind, non-randomized, 1-sequence study involving healthy subjects who have used opioids for recreational use. The primary objective of the study is to establish the pharmacokinetic parameters of morphine 30 mg when administered with and without CBD 350 mg b.i.d. and CBD 700 mg b.i.d.

Conditions

• Opioid Use Disorder

Interventions

Type	Name	Description
DRUG	Morphine Sulfate	Morphine sulfate 30 mg tablets as a single dose twice

Timeline

• Start date: 2021-11-04
• Primary completion: 2023-09-01
• Completion: 2024-12-01
• First posted: 2021-12-03
• Last updated: 2024-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study